Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 11/20 | 0.41 |
| ▸ | JAK1 | P23458 | 11/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1659401 | 0.89 | HDAC2 (0.43) | GPR119HDAC2HDAC1JAK2JAK1 | |
| SCHEMBL2468693 | 0.89 | GPR119 (0.43) | GPR119HDAC2HDAC1JAK2JAK1 | |
| SCHEMBL7527349 | 0.88 | GPR119 (0.44) | GPR119HDAC2HDAC1JAK2JAK1 | |
| SCHEMBL29995192 | 0.88 | GPR119 (0.44) | GPR119HDAC2HDAC1JAK2JAK1 | |
| SCHEMBL31415651 | 0.87 | MEN1 (0.44) | GPR119JAK2JAK1LMNA | |
| SCHEMBL4362609 | 0.84 | GPR119 (0.44) | GPR119HDAC1JAK2JAK1 | |
| SCHEMBL29446735 | 0.84 | GPR119 (0.44) | GPR119HDAC1JAK2JAK1 | |
| SCHEMBL28597678 | 0.83 | USP30 (0.46) | GPR119HDAC2HDAC1JAK2JAK1 | |
| SCHEMBL3925930 | 0.82 | RORC (0.48) | HDAC2HDAC1JAK2JAK1RORC | |
| SCHEMBL19078386 | 0.81 | TACR1 (0.44) | GPR119JAK2JAK1LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2011046771-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | TP53, TP53BP1, MDM2 | GPR119 4605/4885HDAC2 191/4885HDAC1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.